| Year |
Citation |
Score |
| 2022 |
Demus T, Getzenberg RH, Nieder AM. Understanding Prescribing Differences Between Urologists and Medical Oncologists in the Management of Advanced Prostate Cancer. Urology Practice. 10: 90-97. PMID 37103443 DOI: 10.1097/UPJ.0000000000000362 |
0.47 |
|
| 2022 |
Markowski MC, Tutrone R, Pieczonka C, Barnette KG, Getzenberg RH, Rodriguez D, Steiner MS, Saltzstein DR, Eisenberger MA, Antonarakis ES. A Phase 1b/2 Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men With Metastatic Castration-Resistant Prostate Cancer with Progression on an Androgen Receptor Targeting Agent. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35416959 DOI: 10.1158/1078-0432.CCR-22-0162 |
0.498 |
|
| 2020 |
Yu EY, Hancock ML, Aronson W, Flaig T, Belkoff L, Tutrone R, Taylor R, Hardigan PC, Getzenberg RH. Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. PMID 32321673 DOI: 10.1016/j.clgc.2020.03.012 |
0.418 |
|
| 2020 |
Fu S, Liu T, Lv C, Fu C, Zeng R, Kakehi Y, Kulkarni P, Getzenberg RH, Zeng Y. Stromal-epithelial interactions in prostate cancer: Overexpression of PAGE4 in stromal cells inhibits the invasive ability of epithelial cells. Journal of Cellular Biochemistry. PMID 32003504 DOI: 10.1002/jcb.29664 |
0.523 |
|
| 2020 |
Itty S, Getzenberg RH. How do we define "castration" in men on androgen deprivation therapy? Asian Journal of Andrology. PMID 31997782 DOI: 10.4103/aja.aja_139_19 |
0.492 |
|
| 2020 |
Getzenberg RH, Scholz MC, Scholz A, Steiner MS. Survey of ADT-induced estrogen deficiency-related side effects in a contemporary cohort of men with advanced prostate cancer. Journal of Clinical Oncology. 38: 235-235. DOI: 10.1200/Jco.2020.38.6_Suppl.235 |
0.58 |
|
| 2020 |
Getzenberg RH, Lin J, Cerro A, Rhodes CA, Steiner MS. Determination of the ability of a novel, long-acting subcutaneous GnRH antagonist, VERU-100, to castrate without a testosterone surge in a rat model. Journal of Clinical Oncology. 38: 128-128. DOI: 10.1200/Jco.2020.38.6_Suppl.128 |
0.375 |
|
| 2019 |
Ponnusamy S, He Y, Hwang DJ, Thiyagarajan T, Houtman R, Bocharova V, Sumpter BG, Fernandez E, Johnson DL, DU Z, Pfeffer LM, Getzenberg RH, McEwan IJ, Miller DD, Narayanan R. Orally-Bioavailable Androgen Receptor Degrader, A Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31481513 DOI: 10.1158/1078-0432.CCR-19-1458 |
0.492 |
|
| 2019 |
Getzenberg RH, Rodriguez D, Hancock ML, Fisch H, Steiner MS. A phase II, dose finding, placebo-controlled, study of zuclomiphene citrate to amerliorate the frequency and severity of hot flashes caused by androgen deprivation in men with advanced prostate cancer. Journal of Clinical Oncology. 37: TPS338-TPS338. DOI: 10.1200/jco.2019.37.7_suppl.tps338 |
0.366 |
|
| 2019 |
Markowski MC, Eisenberger MA, Antonarakis ES, Yu EY, Barnette G, Rodriguez D, Getzenberg RH, Steiner MS. Design of phase Ib/II study of oral VERU-111, an α and β-tubulin inhibitor, for the treatment of metastatic castration- and androgen-blocking-agent-resistant prostate cancer. Journal of Clinical Oncology. 37: TPS330-TPS330. DOI: 10.1200/Jco.2019.37.7_Suppl.Tps330 |
0.472 |
|
| 2019 |
Getzenberg* R, Markowski M, Steiner M, Eisenberger M, Antonarakis E. MP34-02 VERU-111, A NOVEL ORAL INHIBITOR OF α AND β TUBULIN, INHIBITS TUMOR GROWTH IN THE HUMAN CASTRATION-RESISTANT AR VARIANT PROSTATE CANCER (PCA) MODEL 22RV1 Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555945.38028.Ab |
0.397 |
|
| 2019 |
Getzenberg R, Rodriguez D, Hancock M, Fisch H, Steiner M. A phase 2, dose finding, placebo-controlled, study of zuclomiphene citrate to alleviate the frequency and severity of hot flashes caused by androgen deprivation in men with advanced prostate cancer European Urology Supplements. 18: e1826. DOI: 10.1016/S1569-9056(19)31323-5 |
0.565 |
|
| 2019 |
Getzenberg R, Markowski M, Eisenberger M, Antonarakis E, Yu E, Barnette G, Rodriguez D, Steiner M. Design of phase 1b/2 study of oral VERU-111, an α and β-tubulin inhibitor, for the treatment of metastatic castration and androgen blocking agent resistant prostate cancer European Urology Supplements. 18: e1825. DOI: 10.1016/S1569-9056(19)31322-3 |
0.495 |
|
| 2019 |
Getzenberg R, Markowski M, Eisenberger M, Steiner M, Antonarakis E. VERU-111, a novel oral inhibitor of α and β tubulin, inhibits tumor growth in the human castration-resistant AR variant prostate cancer (PCa) model 22Rv1 European Urology Supplements. 18: e1348. DOI: 10.1016/s1569-9056(19)30976-5 |
0.41 |
|
| 2018 |
Getzenberg RH, Dalton JT, Miller DD, Steiner MS. Activity of VERU-111, an novel oral α and β tubulin inhibitor, against paclitaxel sensitive and resistant prostate cancer. Journal of Clinical Oncology. 36: 302-302. DOI: 10.1200/Jco.2018.36.6_Suppl.302 |
0.449 |
|
| 2018 |
Markowski MC, Getzenberg RH, Steiner MS, Azad NS, Gaillard S, Eisenberger MA, Antonarakis ES. Effect of VERU-111, a novel oral inhibitor of α and β tubulin, on tumor growth in the human castration-resistant prostate cancer model 22Rv1. Journal of Clinical Oncology. 36: e17003-e17003. DOI: 10.1200/Jco.2018.36.15_Suppl.E17003 |
0.376 |
|
| 2018 |
Getzenberg R, Dalton J, Miller D, Steiner M. VERU-111, an novel oral α and β tubulin inhibitor, has potent activity against paclitaxel sensitive and resistant prostate cancer European Urology Supplements. 17: e504. DOI: 10.1016/S1569-9056(18)31195-3 |
0.508 |
|
| 2018 |
Getzenberg R, Dalton J, Miller D, Steiner M. MP52-02 A NOVEL ORAL ? AND ? TUBULIN INHIBITOR, VERU-111, HAS POTENT ACTIVITY AGAINST PACLITAXEL SENSITIVE AND RESISTANT PROSTATE CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1653 |
0.575 |
|
| 2017 |
Getzenberg R, Ponnusamy S, Thiyagarajan T, Hwang D, He Y, McEwan I, Watt C, Moldoveanu T, Miller D, Narayanan R. Identification and characterization of selective androgen receptor degraders (SARDs) for the treatment of enzalutamide unresponsive and/or resistant prostate cancer European Urology Supplements. 16: e1288-e1289. DOI: 10.1016/J.Juro.2017.02.1777 |
0.593 |
|
| 2017 |
Ponnusamy S, Getzenberg R, Thiyagarajan T, Hwang D, He Y, McEwan I, Watt C, Moldoveanu T, Miller D, Narayanan R. MP57-03 IDENTIFICATION AND CHARACTERIZATION OF SELECTIVE ANDROGEN RECEPTOR DEGRADERS (SARDS) FOR THE TREATMENT OF ENZALUTAMIDE UNRESPONSIVE AND/OR RESISTANT PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/j.juro.2017.02.1777 |
0.515 |
|
| 2016 |
Kulkarni P, Getzenberg RH. Disorder, Promiscuous Interactions, and Stochasticity Regulate State Switching in the Unstable Prostate. Journal of Cellular Biochemistry. PMID 27152744 DOI: 10.1002/jcb.25578 |
0.466 |
|
| 2016 |
Yu EY, Hancock ML, Babicz T, Tutrone RF, Ng C, Belkoff LH, Aronson WJ, Papai Z, Geczi L, Getzenberg RH. A phase II open-label trial of GTx-758 in men with castration-resistant prostate cancer: Final analysis of the primary endpoint. Journal of Clinical Oncology. 34: 185-185. DOI: 10.1200/Jco.2016.34.2_Suppl.185 |
0.413 |
|
| 2016 |
Aronson W, Yu E, Hancock M, Babicz T, Tutrone R, Ng C, Belkoff L, Pápai Z, Géczi L, Getzenberg R. PD32-03 A PHASE 2 OPEN-LABEL TRIAL OF GTX-758 IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER, FINAL ANALYSIS OF THE PRIMARY ENDPOINT Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.679 |
0.562 |
|
| 2015 |
Takahashi S, Shiraishi T, Miles N, Trock BJ, Kulkarni P, Getzenberg RH. Nanowire analysis of cancer-testis antigens as biomarkers of aggressive prostate cancer. Urology. 85: 704.e1-7. PMID 25733303 DOI: 10.1016/J.Urology.2014.12.004 |
0.666 |
|
| 2015 |
Liu Z, Zhu G, Getzenberg RH, Veltri RW. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer. Journal of Cellular Biochemistry. 116: 1341-9. PMID 25640606 DOI: 10.1002/jcb.25091 |
0.4 |
|
| 2015 |
Yu EY, Getzenberg RH, Coss CC, Gittelman MM, Keane T, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Hancock ML, Smith J, et al. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. European Urology. 67: 334-41. PMID 24968970 DOI: 10.1016/j.eururo.2014.06.011 |
0.547 |
|
| 2015 |
Yu EY, Hancock ML, Babicz T, Aronson WJ, Papai Z, Geczi L, Getzenberg RH. Evaluation of the ERα agonist, GTx-758 (250 mg daily), in men with metastatic (mCRPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology. 33: 201-201. DOI: 10.1200/Jco.2015.33.7_Suppl.201 |
0.374 |
|
| 2015 |
Yu EY, Hancock ML, Babicz T, Aronson WJ, Papai Z, Geczi L, Getzenberg RH. Effect of the ERα agonist, GTx-758 (250 mg daily), on total and free testosterone, and PSA, in men with castration resistant prostate cancer (CRPC) maintained on LHRH therapy. Journal of Clinical Oncology. 33: e16020-e16020. DOI: 10.1200/JCO.2015.33.15_SUPPL.E16020 |
0.514 |
|
| 2015 |
Getzenberg R, Yu E, Hancock M, Babicz T, Aronson W, Pápai Z, Géczi L. 568 Evaluation of the ERα agonist, GTx-758 (250 mg daily), in men with metastatic (mCRPC) and non-metastatic castration resistant prostate cancer (nmCRPC) European Urology Supplements. 14: e568. DOI: 10.1016/S1569-9056(15)60561-9 |
0.516 |
|
| 2015 |
Yu E, Hancock M, Babicz T, Aronson W, Pápai Z, Géczi L, Getzenberg R. MP87-03 EVALUATION OF THE ERα AGONIST, GTX-758 (250 MG DAILY), IN MEN WITH METASTATIC (MCRPC) AND NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER (NMCRPC) Journal of Urology. 193. DOI: 10.1016/S1569-9056(15)60561-9 |
0.594 |
|
| 2015 |
Takahashi S, Takada I, Terada N, Getzenberg R, Homma Y. 278 Androgen receptor positive stromal cells regulate prostate cancer proliferation through noncanonical Wnt signaling European Urology Supplements. 14: e278. DOI: 10.1016/S1569-9056(15)60275-5 |
0.634 |
|
| 2015 |
Liu Z, Zhu G, Getzenberg RH, Veltri RW. The upregulation of PI3K/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer Journal of Cellular Biochemistry. 116: 1341-1349. DOI: 10.1002/jcb.25091 |
0.4 |
|
| 2014 |
McNeil BK, Sorbellini M, Grubb RL, Apolo A, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, Netto GJ, Shih J, Linehan WM, et al. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. Journal of Translational Medicine. 12: 199. PMID 25335552 DOI: 10.1186/1479-5876-12-199 |
0.428 |
|
| 2014 |
Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, Takahashi S, Luo J, Lupold SE, Kulkarni P, Getzenberg RH. Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation. Journal of Cellular Biochemistry. 115: 1505-15. PMID 24604720 DOI: 10.1002/Jcb.24805 |
0.554 |
|
| 2014 |
Mukherjee A, Darlington T, Baldwin R, Holz C, Olson S, Kulkarni P, DeWeese TL, Getzenberg RH, Ivkov R, Lupold SE. Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen. Chemmedchem. 9: 1356-60. PMID 24591351 DOI: 10.1002/Cmdc.201300549 |
0.435 |
|
| 2014 |
Myers-Irvin JM, Getzenberg RH. Retraction: Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology. Cancer Research. 74: 974. PMID 24492705 DOI: 10.1158/0008-5472.Can-13-3721 |
0.493 |
|
| 2014 |
Getzenberg RH. Tools to identify the men with prostate cancer most appropriate for active surveillance? Asian Journal of Andrology. 16: 97-8. PMID 24369138 DOI: 10.4103/1008-682X.122369 |
0.576 |
|
| 2014 |
Aw Yong KM, Zeng Y, Vindivich D, Phillip JM, Wu PH, Wirtz D, Getzenberg RH. Morphological effects on expression of growth differentiation factor 15 (GDF15), a marker of metastasis. Journal of Cellular Physiology. 229: 362-73. PMID 23996089 DOI: 10.1002/Jcp.24458 |
0.415 |
|
| 2014 |
Yu EY, Getzenberg RH, Smith J, Hancock ML, Tutrone R, Flaig TW, Dalton JT, Steiner MS, Westenfelder KR, Szucs M. The effect of low-dose GTx-758 on free testerone levels in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 32: 60-60. DOI: 10.1200/Jco.2014.32.4_Suppl.60 |
0.483 |
|
| 2014 |
Yu EY, Getzenberg RH, Smith J, Hancock ML, Smith MR, Malkowicz SB, Sieber P, Dalton JT, Steiner MS. Optimal testosterone suppression on medical ADT should strive to suppress free testosterone levels to levels similar to orchiectomy: What is that value? Journal of Clinical Oncology. 32: 144-144. DOI: 10.1200/Jco.2014.32.4_Suppl.144 |
0.421 |
|
| 2014 |
Getzenberg R, Yu E, Smith J, Hancock M, Tutrone R, Flaig T, Westenfelder K, Szucs M, Dalton J, Steiner M. 863 Low dose GTx-758 decreases free testosterone to levels similar to orchiectomy in men with metastatic castration resistant prostate cancer (mCRPC) European Urology Supplements. 13: e863. DOI: 10.1016/S1569-9056(14)60850-2 |
0.596 |
|
| 2014 |
Takahashi S, Terada N, Zeng Y, Shiraishi T, Homma Y, Getzenberg R. 838 Non-canonical Wnt signaling promotes prostate cancer growth by increasing growth factors from stromal cells and plays a key role on stromal-epithelial cell communication European Urology Supplements. 13: e838. DOI: 10.1016/S1569-9056(14)60825-3 |
0.403 |
|
| 2014 |
Takahashi S, Terada N, Zeng Y, Shiraishi T, Homma Y, Getzenberg RH. MP31-11 NON-CANONICAL WNT SIGNALING PROMOTES PROSTATE CANCER GROWTH BY INCREASING GROWTH FACTORS FROM STROMAL CELLS AND PLAYS A KEY ROLE IN STROMAL-EPITHELIAL COMMUNICATION Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.920 |
0.449 |
|
| 2014 |
Getzenberg RH, Kulkarni P. Etiology and Pathogenesis Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. 1-9. DOI: 10.1002/9781118437889.ch1 |
0.368 |
|
| 2013 |
Keane TE, Tutrone R, Belkoff L, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Getzenberg RH, Coss C, Hancock ML, Dalton JT, Steiner MS. Effect of the ERα agonist GTx-758 on bone turnover markers in men with advanced prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 222. PMID 28137016 DOI: 10.1200/Jco.2013.31.6_Suppl.222 |
0.563 |
|
| 2013 |
Gittelman M, Keane TE, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Getzenberg RH, Coss C, Hancock ML, Dalton JT, Steiner MS. Effect of GTx-758, an ERα agonist, on serum-free testosterone and serum PSA in men with advanced prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 104. PMID 28137010 DOI: 10.1200/Jco.2013.31.6_Suppl.104 |
0.633 |
|
| 2013 |
Gittelman M, Keane TE, Tutrone R, Belkoff L, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Getzenberg RH, Coss C, Hancock ML, Dalton JT, Steiner MS. Rate of hot flashes in patients with advanced prostate cancer treated with GTx-758. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 129. PMID 28136791 DOI: 10.1200/Jco.2013.31.6_Suppl.129 |
0.598 |
|
| 2013 |
Gittelman M, Keane TE, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Getzenberg RH, Coss C, Hancock ML, Dalton JT, Steiner MS. Serum IGF-1 levels in men with advanced prostate cancer treated with the ERα agonist, GTx-758. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 171. PMID 28136777 DOI: 10.1200/Jco.2013.31.6_Suppl.171 |
0.613 |
|
| 2013 |
Zeng Y, Gao D, Kim JJ, Shiraishi T, Terada N, Kakehi Y, Kong C, Getzenberg RH, Kulkarni P. Prostate-associated gene 4 (PAGE4) protects cells against stress by elevating p21 and suppressing reactive oxygen species production. American Journal of Clinical and Experimental Urology. 1: 39-52. PMID 25374899 |
0.54 |
|
| 2013 |
Van Le TS, Myers J, Getzenberg RH, Konety BR, Barder T. Retraction: Functional characterization of the bladder cancer marker, BLCA-4. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3327. PMID 23709676 DOI: 10.1158/1078-0432.CCR-13-1145 |
0.375 |
|
| 2013 |
Zeng Y, Wodzenski D, Gao D, Shiraishi T, Terada N, Li Y, Vander Griend DJ, Luo J, Kong C, Getzenberg RH, Kulkarni P. Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing. Cancer Research. 73: 4123-33. PMID 23667174 DOI: 10.1158/0008-5472.Can-12-1343 |
0.583 |
|
| 2013 |
Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Science Translational Medicine. 5: 169ra10. PMID 23345608 DOI: 10.1126/Scitranslmed.3005211 |
0.424 |
|
| 2013 |
Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH. Retraction: Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 508. PMID 23271798 DOI: 10.1158/1078-0432.Ccr-12-2711 |
0.414 |
|
| 2013 |
Schoen RE, Weissfeld JL, Sokoll LJ, Chan DW, Cannon GW, Getzenberg RH. Retraction. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Research. 73: 1034. PMID 23271721 DOI: 10.1158/0008-5472.Can-12-3286 |
0.512 |
|
| 2013 |
Kim JJ, Yin B, Christudass CS, Terada N, Rajagopalan K, Fabry B, Lee DY, Shiraishi T, Getzenberg RH, Veltri RW, An SS, Mooney SM. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. Journal of Cellular Biochemistry. 114: 1286-93. PMID 23192682 DOI: 10.1002/Jcb.24464 |
0.444 |
|
| 2013 |
Jones ML, Siddiqui J, Pienta KJ, Getzenberg RH. Circulating fibroblast-like cells in men with metastatic prostate cancer. The Prostate. 73: 176-81. PMID 22718300 DOI: 10.1002/Pros.22553 |
0.675 |
|
| 2013 |
Matsumoto AM, Getzenberg RH, Coss C, Hancock ML, Si X, Dalton JT, Steiner MS. The free hormone hypothesis: Correlation of decreases in PSA with free testosterone rather than total testosterone in men with advanced prostate cancer treated with GTx-758. Journal of Clinical Oncology. 31: e16015-e16015. DOI: 10.1200/JCO.2013.31.15_SUPPL.E16015 |
0.3 |
|
| 2013 |
Takahashi S, Shiraishi T, Trock B, Kulkarni P, Getzenberg R, Tominaga T, Homma Y. 1048 CSAG4 and NOL4 are novel biomarkers to indicate aggressiveness of prostate cancer European Urology Supplements. 12: e1048. DOI: 10.1016/S1569-9056(13)61524-9 |
0.684 |
|
| 2013 |
Getzenberg R, Coss C, Hancock M, Dalton J, Steiner M. 102 GTx-758, an ERα agonist, reduces serum free testosterone lower than can be achieved by leuprolide with a significantly lower rate of hot flashes in men with advanced prostate cancer European Urology Supplements. 12: e102-e103. DOI: 10.1016/S1569-9056(13)60594-1 |
0.615 |
|
| 2013 |
Shiraishi T, Terada N, Mooney S, Zeng Y, Takahashi S, Luo J, Getzenberg R, Kulkarni P. 804 OVEREXPRESSION OF THE CANCER/TESTIS ANTIGEN JARID1B, CONTRIBUTES TO THE SURVIVAL OF PROSTATE CANCER CELLS UNDER ANDROGEN DEPLETED CONDITIONS Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.368 |
0.628 |
|
| 2013 |
Zeng Y, Gao D, Wodzenski D, Shiraishi T, Terada N, Luo J, Getzenberg R, Kulkarni P. 1323 RNA-BINDING MOTIF PROTEIN 3 ATTENUATES THE STEM CELL-LIKE PROPERTIES OF PROSTATE CANCER CELLS BY INTERFERING WITH CD44 VARIANT SPLICING Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2677 |
0.511 |
|
| 2012 |
Li J, Zhang ZH, Yin CJ, Pavlovich C, Luo J, Getzenberg R, Zhang W. Effect of surgical procedures on prostate tumor gene expression profiles. Asian Journal of Andrology. 14: 708-14. PMID 22864281 DOI: 10.1038/Aja.2012.54 |
0.362 |
|
| 2012 |
Leman ES, Magheli A, Cannon GW, Mangold L, Partin AW, Getzenberg RH. Erratum: Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2 (Prostate (2009) 69 (1188-1194)) The Prostate. 72. PMID 22803194 DOI: 10.1002/Pros.22529 |
0.848 |
|
| 2012 |
Kulkarni P, Shiraishi T, Rajagopalan K, Kim R, Mooney SM, Getzenberg RH. Cancer/testis antigens and urological malignancies. Nature Reviews. Urology. 9: 386-96. PMID 22710665 DOI: 10.1038/Nrurol.2012.117 |
0.512 |
|
| 2012 |
Getzenberg RH, Carter HB. Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer. Asian Journal of Andrology. 14: 347-8. PMID 22522499 DOI: 10.1038/Aja.2012.34 |
0.681 |
|
| 2012 |
Shiraishi T, Getzenberg RH, Kulkarni P. Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer. Asian Journal of Andrology. 14: 400-4. PMID 22343492 DOI: 10.1038/Aja.2011.144 |
0.693 |
|
| 2012 |
Terada N, Kulkarni P, Getzenberg RH. Cyr61 is a potential prognostic marker for prostate cancer. Asian Journal of Andrology. 14: 405-8. PMID 22343491 DOI: 10.1038/Aja.2011.149 |
0.638 |
|
| 2012 |
Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, et al. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prevention Research (Philadelphia, Pa.). 5: 621-30. PMID 22293631 DOI: 10.1158/1940-6207.Capr-11-0455 |
0.374 |
|
| 2012 |
Terada N, Shiraishi T, Zeng Y, Mooney SM, Yeater DB, Mangold LA, Partin AW, Kulkarni P, Getzenberg RH. Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness. The Prostate. 72: 966-76. PMID 22025384 DOI: 10.1002/Pros.21501 |
0.507 |
|
| 2012 |
Jones ML, Ewing CM, Isaacsa WB, Getzenberg RH. Prostate cancer-derived angiogenin stimulates the invasion of prostate fibroblasts. Journal of Cellular and Molecular Medicine. 16: 193-201. PMID 21352472 DOI: 10.1111/J.1582-4934.2011.01283.X |
0.68 |
|
| 2012 |
Terada N, Shiraishi T, Zeng Y, Aw-Yong K, Mooney SM, Luo J, Kulkarni P, Getzenberg RH. Abstract C44: The identification and characterization of androgen-independent cells prior to hormonal manipulation in prostate cancer Cancer Research. 72: C44-C44. DOI: 10.1158/1538-7445.Prca2012-C44 |
0.586 |
|
| 2012 |
Yong KMA, Zeng Y, Vindivich D, Getzenberg R. Abstract 5188: Altering cell attachment to growth substrate up-regulates growth differentiation factor 15 (GDF15) expression Cancer Research. 72: 5188-5188. DOI: 10.1158/1538-7445.Am2012-5188 |
0.56 |
|
| 2012 |
Christudass C, Sood K, Yeater D, Getzenberg R, Veltri R. 789 TAXOL RESISTANCE IN PROSTATE CANCER RESCUE OF RESISTANCE AND EXPRESSION OF PROSTATE CANCER-ASSOCIATED GENES UPON TREATMENT WITH HDAC INHIBITORS Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.877 |
0.624 |
|
| 2012 |
Terada N, Shiraishi T, Zeng Y, Aw-Yong K, Mooney S, Luo J, Kulkarni P, Getzenberg R. 958 THE IDENTIFICATION AND CHARACTERIZATION OF ANDROGEN-INDEPENDENT CELLS PRIOR TO HORMONAL MANIPULATION IN PROSTATE CANCER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.1057 |
0.67 |
|
| 2011 |
Sorbellini M, McNeil B, Cohen B, Athauda G, Giubellino A, Coleman J, Netto GJ, Getzenberg RH, Linehan W, Bottaro DP. Urinary Met level as a novel biomarker for urothelial carcinoma of the bladder. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 257. PMID 27968502 DOI: 10.1200/Jco.2011.29.7_Suppl.257 |
0.44 |
|
| 2011 |
Getzenberg RH, Coffey DS. Changing the energy habitat of the cancer cell in order to impact therapeutic resistance. Molecular Pharmaceutics. 8: 2089-93. PMID 21919453 DOI: 10.1021/Mp200310U |
0.456 |
|
| 2011 |
Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, Kulkarni P, Getzenberg RH. Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. Journal of Translational Medicine. 9: 153. PMID 21917134 DOI: 10.1186/1479-5876-9-153 |
0.606 |
|
| 2011 |
Rajagopalan K, Mooney SM, Parekh N, Getzenberg RH, Kulkarni P. A majority of the cancer/testis antigens are intrinsically disordered proteins. Journal of Cellular Biochemistry. 112: 3256-67. PMID 21748782 DOI: 10.1002/Jcb.23252 |
0.431 |
|
| 2011 |
Liu L, Sun B, Pedersen JN, Aw Yong KM, Getzenberg RH, Stone HA, Austin RH. Probing the invasiveness of prostate cancer cells in a 3D microfabricated landscape. Proceedings of the National Academy of Sciences of the United States of America. 108: 6853-6. PMID 21474778 DOI: 10.1073/Pnas.1102808108 |
0.579 |
|
| 2011 |
Li Y, Zeng Y, Mooney SM, Yin B, Mizokami A, Namiki M, Getzenberg RH. Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. Journal of Cellular Biochemistry. 112: 2125-37. PMID 21465536 DOI: 10.1002/Jcb.23134 |
0.428 |
|
| 2011 |
Kulkarni P, Rajagopalan K, Yeater D, Getzenberg RH. Protein folding and the order/disorder paradox. Journal of Cellular Biochemistry. 112: 1949-52. PMID 21445877 DOI: 10.1002/Jcb.23115 |
0.305 |
|
| 2011 |
Zeng Y, He Y, Yang F, Mooney SM, Getzenberg RH, Orban J, Kulkarni P. The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. The Journal of Biological Chemistry. 286: 13985-94. PMID 21357425 DOI: 10.1074/Jbc.M110.210765 |
0.552 |
|
| 2011 |
Mooney SM, Rajagopalan K, Williams BH, Zeng Y, Christudass CS, Li Y, Yin B, Kulkarni P, Getzenberg RH. Creatine kinase brain overexpression protects colorectal cells from various metabolic and non-metabolic stresses. Journal of Cellular Biochemistry. 112: 1066-75. PMID 21308735 DOI: 10.1002/Jcb.23020 |
0.38 |
|
| 2011 |
Terada N, Zeng Y, Kulkarni P, Getzenberg RH. Abstract 1414: Lysophosphatidic acid-induced Cyr61 is associated with prostate cancer progression Cancer Research. 71: 1414-1414. DOI: 10.1158/1538-7445.Am2011-1414 |
0.528 |
|
| 2011 |
Zeng Y, Shirashi T, Kim J, Mooney S, Meeker A, Luo J, Getzenberg R, Kulkarni P. 139 THE STRESS RESPONSE PROTEIN, PROSTATE ASSOCIATED GENE 4, IS ASSOCIATED WITH LESS AGGRESSIVE PROSTATE CANCER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.206 |
0.648 |
|
| 2011 |
Terada N, Kulkarni P, Getzenberg R. 129 CYR61 IS A POTENTIAL SERUM MARKER FOR IDENTIFYING NON-ORGAN-CONFINED PROSTATE CANCER Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.196 |
0.635 |
|
| 2011 |
Huang H, Getzenberg R, Kulkarni P, Shapiro E. 1577 THE TEMPORAL EXPRESSION OF JM-27 IN HUMAN FETAL PROSTATE Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1613 |
0.53 |
|
| 2011 |
Jones A, Getzenberg RH, Dalton JT, Veverka KA. 1448 ORAL ADMINISTRATION OF GTX-758, A SELECTIVE ERα AGONIST, INDUCES CHEMICAL CASTRATION BUT NOT GYNECOMASTIA IN MALE MONKEYS Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1361 |
0.486 |
|
| 2010 |
D'Antonio KB, Schultz L, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH. Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5908-13. PMID 21138874 DOI: 10.1158/1078-0432.Ccr-10-1200 |
0.604 |
|
| 2010 |
Getzenberg RH. Novel approaches for the molecular classification of prostate cancer. Asian Journal of Andrology. 12: 620-2. PMID 20711216 DOI: 10.1038/Aja.2010.95 |
0.686 |
|
| 2010 |
Getzenberg RH. Statins and the risk of prostate cancer or benign prostatic hyperplasia: biological plausibility. The Journal of Urology. 184: 415-6. PMID 20620390 DOI: 10.1016/J.Juro.2010.05.045 |
0.641 |
|
| 2010 |
Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, Luo J, Getzenberg RH, Kulkarni P. Expression of cancer/testis antigens in prostate cancer is associated with disease progression. The Prostate. 70: 1778-87. PMID 20583133 DOI: 10.1002/Pros.21214 |
0.595 |
|
| 2010 |
Liu L, Loutherback K, Liao D, Yeater D, Lambert G, Estévez-Torres A, Sturm JC, Getzenberg RH, Austin RH. A microfluidic device for continuous cancer cell culture and passage with hydrodynamic forces. Lab On a Chip. 10: 1807-13. PMID 20424729 DOI: 10.1039/C003509B |
0.387 |
|
| 2010 |
D'Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH. Extracellular matrix associated protein CYR61 is linked to prostate cancer development. The Journal of Urology. 183: 1604-10. PMID 20172544 DOI: 10.1016/J.Juro.2009.12.006 |
0.68 |
|
| 2010 |
Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB, Pavlovich CP. Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. The Prostate. 70: 473-81. PMID 19902472 DOI: 10.1002/Pros.21081 |
0.57 |
|
| 2010 |
Sorbellini M, McNeil B, Simpson H, Giubellino A, Hsieh T, Getzenberg RH, Schoenberg M, Gagani C, Bottaro DP. Correlation of Met expression in TCC of the bladder with stage and grade. Journal of Clinical Oncology. 28: e15110-e15110. DOI: 10.1200/Jco.2010.28.15_Suppl.E15110 |
0.432 |
|
| 2010 |
Suyama T, Shiraishi T, Zeng Y, Yu W, Getzenberg R, Kulkarni P. 553 MAGEA2B A NOVEL THERAPEUTIC CANDIDATE FOR HORMONE-REFRACTORY PROSTATE CANCER Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.773 |
0.675 |
|
| 2010 |
Zeng Y, Suyama T, Getzenberg R, Kulkarni P. 1180 CANCER/TESTIS ANTIGENS AND PROSTATE CANCER: SILENCING PROSTATE-ASSOCIATED ANTIGEN-4 (PAGE4) BY RNA INTERFERENCE ATTENUATES TUMOR GROWTH Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.681 |
0.634 |
|
| 2009 |
McNeil BK, Getzenberg RH. Urinary protein biomarkers of cancer. Expert Opinion On Medical Diagnostics. 3: 263-73. PMID 23488462 DOI: 10.1517/17530050902824811 |
0.353 |
|
| 2009 |
Leman ES, Magheli A, Yong KM, Netto G, Hinz S, Getzenberg RH. Identification of nuclear structural protein alterations associated with seminomas. Journal of Cellular Biochemistry. 108: 1274-9. PMID 19795381 DOI: 10.1002/Jcb.22357 |
0.753 |
|
| 2009 |
Getzenberg RH, Partin AW. The lance armstrong effect: Applying testicular cancer's treatment success to prostate cancer Bjui. 104. PMID 19706032 DOI: 10.1111/J.1464-410X.2009.08884.X |
0.644 |
|
| 2009 |
Leman ES, Getzenberg RH. Biomarkers for prostate cancer. Journal of Cellular Biochemistry. 108: 3-9. PMID 19507229 DOI: 10.1002/Jcb.22227 |
0.855 |
|
| 2009 |
Leman ES, Magheli A, Cannon GW, Mangold L, Partin AW, Getzenberg RH. Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2 Prostate. 69: 1188-1194. PMID 19418497 DOI: 10.1002/Pros.20963 |
0.822 |
|
| 2009 |
Zeng Y, Kulkarni P, Inoue T, Getzenberg RH. Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. Journal of Cellular Biochemistry. 107: 179-88. PMID 19277990 DOI: 10.1002/Jcb.22114 |
0.569 |
|
| 2009 |
Inoue T, Maeno A, Talbot C, Zeng Y, Yeater DB, Leman ES, Kulkarni P, Ogawa O, Getzenberg RH. Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells. The Prostate. 69: 861-73. PMID 19267365 DOI: 10.1002/Pros.20936 |
0.845 |
|
| 2009 |
Kulkarni P, Getzenberg RH. High-fat diet, obesity and prostate disease: The ATX-LPA axis? Nature Clinical Practice Urology. 6: 128-131. PMID 19204739 DOI: 10.1038/Ncpuro1311 |
0.498 |
|
| 2009 |
Getzenberg RH. Comment on "Treatment of chronic prostatitis in Chinese men" by Liang CZ et al. in Asian Journal of Andrology. Asian Journal of Andrology. 11: 149. PMID 19151737 DOI: 10.1038/Aja.2008.47 |
0.441 |
|
| 2009 |
Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annual Review of Medicine. 60: 139-51. PMID 18947298 DOI: 10.1146/annurev.med.60.042307.110714 |
0.618 |
|
| 2009 |
Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB, Pavlovich CP. MONOCYTE CHEMOTACTIC PROTEIN-1 (MCP-1:CCL2) IS ASSOCIATED WITH PROSTATIC GROWTH DYSREGULATION Journal of Urology. 181: 505-506. DOI: 10.1016/S0022-5347(09)61427-0 |
0.549 |
|
| 2009 |
Zeng Y, Kulkarni P, Getzenberg RH. ATTENUATING THE EXPRESSION OF A CANCER TESTIS ANTIGEN PAGE4, IMPAIRS CELL SURVIVAL AND SYNERGIZES CHEMOTHERAPY IN PROSTATE CANCER CELLS Journal of Urology. 181: 396-396. DOI: 10.1016/S0022-5347(09)61123-X |
0.623 |
|
| 2009 |
Zeng Y, Kulkarni P, Getzenberg RH. A NOVEL MECHANISM FOR MODULATING THE RESPONSE OF PROSTATE CANCER TO CHEMOTHERAPY: THE COLD SHOCK RESPONSE PATHWAY Journal of Urology. 181: 260-260. DOI: 10.1016/S0022-5347(09)60741-2 |
0.559 |
|
| 2009 |
Inoue T, Maeno A, Kulkarni P, Zeng Y, Yeater DB, Leman ES, Ogawa O, Getzenberg RH. Purine-Rich Element Binding Protein Alpha Induces Cell Stress And Differentiation Pathways In Prostate Cancer Cells The Journal of Urology. 181: 189-189. DOI: 10.1016/S0022-5347(09)60545-0 |
0.548 |
|
| 2009 |
Leman ES, Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH. W1889 Blood-Based Detection of Colon Cancer Utilizing Specific Nuclear Matrix Proteins Gastroenterology. 136: A-748. DOI: 10.1016/S0016-5085(09)63448-X |
0.764 |
|
| 2009 |
Inoue T, Maeno A, Kulkarni P, Zeng Y, Yeater D, Leman E, Ogawa O, Getzenberg R. POD-04.01: Purine-Rich Element Binding Protein Alpha Induces Cell Stress and Differentiation Pathways in Prostate Cancer Cells Urology. 74: S10. DOI: 10.1016/j.urology.2009.07.1177 |
0.792 |
|
| 2008 |
Cannon GW, Getzenberg RH. Biomarkers for benign prostatic hyperplasia progression Current Urology Reports. 9: 279-283. PMID 18765126 DOI: 10.1007/S11934-008-0049-5 |
0.504 |
|
| 2008 |
Getzenberg R. What is the future of prostate-specific antigen for the early detection of prostate cancer? Bju International. 102: 157-8. PMID 18476972 DOI: 10.1111/J.1464-410X.2008.07694.X |
0.659 |
|
| 2008 |
Babjuk M, Soukup V, Pesl M, Kostírová M, Drncová E, Smolová H, Szakacsová M, Getzenberg R, Pavlík I, Dvorácek J. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology. 71: 718-22. PMID 18387400 DOI: 10.1016/J.Urology.2007.12.021 |
0.392 |
|
| 2008 |
Inoue T, Leman ES, Yeater DB, Getzenberg RH. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer. The Prostate. 68: 1048-56. PMID 18386260 DOI: 10.1002/Pros.20764 |
0.839 |
|
| 2008 |
Thomas CA, Grant SG, Pflug BR, Getzenberg RH, Day BW. (Z)-1,1-Dichloro-2-(4-methoxyphenyl)-3-phenylcyclopropane induces concentration-dependent growth inhibition, apoptosis, and coordinates regulation of apoptotic genes in TRAMP cells. Urologic Oncology. 26: 378-85. PMID 18367102 DOI: 10.1016/J.Urolonc.2007.02.013 |
0.376 |
|
| 2008 |
Leman ES, Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH. Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer Clinical Cancer Research. 14: 1349-1354. PMID 18316554 DOI: 10.1158/1078-0432.Ccr-07-4110 |
0.787 |
|
| 2008 |
McNeil BK, Getzenberg RH. Urine-based markers in bladder cancer: future prospects. Bju International. 101: 668-9. PMID 18291016 DOI: 10.1111/J.1464-410X.2007.07439.X |
0.496 |
|
| 2008 |
Mullins C, Lucia MS, Hayward SW, Lee JY, Levitt JM, Lin VK, Liu BC, Chinnaiyan AM, Rubin MA, Slawin K, Star RA, Getzenberg RH. A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium. The Journal of Urology. 179: 1243-56. PMID 18280515 DOI: 10.1016/J.Juro.2007.11.049 |
0.56 |
|
| 2008 |
Walgenbach-Brunagel G, Burger B, Leman ES, Walgenbach KJ, Tolba R, Heukamp L, Hirner A, Getzenberg RH. The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer. Journal of Cellular Biochemistry. 104: 286-94. PMID 18044711 DOI: 10.1002/Jcb.21619 |
0.791 |
|
| 2008 |
Leman ES, Getzenberg RH. Nuclear structure as a source of cancer specific biomarkers. Journal of Cellular Biochemistry. 104: 1988-93. PMID 17455233 DOI: 10.1002/Jcb.21363 |
0.82 |
|
| 2008 |
Fujita K, Ewing CM, Chan D, Magnold L, Partin AW, Getzenberg RH, Isaacs WB, Pavlovich CP. ENDOGLIN (CD105) AS A POTENTIAL URINARY MARKER FOR PROSTATE CANCER DETECTION Journal of Urology. 179: 720-720. DOI: 10.1016/S0022-5347(08)62099-6 |
0.592 |
|
| 2008 |
Leman ES, Magheli A, Cannon GW, Sokoll LJ, Chan DW, Mangold LA, Partin AW, Getzenberg RH, Getzenberg RH. ANALYSIS OF A SECOND EPCA-2 EPITOPE AS A SERUM TEST FOR PROSTATE CANCER Journal of Urology. 179: 704-704. DOI: 10.1016/S0022-5347(08)62052-2 |
0.846 |
|
| 2008 |
D'Antonio K, Toubaji A, Albadine R, Netto GJ, Getzenberg RH. EXPRESSION OF THE EXTRACELLULAR MATRIX ASSOCIATED PROTEIN CYR61 IS ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CANCER Journal of Urology. 179: 459-459. DOI: 10.1016/S0022-5347(08)61347-6 |
0.798 |
|
| 2008 |
Inoue T, Leman ES, Yeater D, Getzenberg RH. PURINE-ELEMENT BINDING PROTEIN (PUR) α AS A NOVEL TREATMENT TARGET FOR HORMONE-REFRACTORY PROSTATE CANCER Journal of Urology. 179: 46-47. DOI: 10.1016/S0022-5347(08)60140-8 |
0.816 |
|
| 2008 |
Christodouleas J, Yeater D, Jabbour S, Mangold L, Leman E, Drew R, Humphreys E, Partin A, Getzenberg R, DeWeese T. Modulation of EPCA-2 Levels in Men with Localized Prostate Cancer Treated with Radiation with or without Androgen Suppression Therapy International Journal of Radiation Oncology*Biology*Physics. 72: S316. DOI: 10.1016/J.Ijrobp.2008.06.1091 |
0.813 |
|
| 2008 |
Cannon GW, Getzenberg RH. JM-27: A biomarker for symptomatic benign prostatic hyperplasia and lower urinary tract symptoms Current Prostate Reports. 6: 19-23. DOI: 10.1007/S11918-008-0004-4 |
0.463 |
|
| 2007 |
Keller ET, Rowley DR, Tomlins SA, Drake CG, Kantoff PW, Pienta KJ, Montie JE, Carter HB, Hruszkewicz AM, Gomez J, Mohla S, Getzenberg RH. Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Research. 67: 9613-5. PMID 17928375 DOI: 10.1158/0008-5472.Can-07-1529 |
0.659 |
|
| 2007 |
Leman ES, Schoen RE, Weissfeld JL, Cannon GW, Sokoll LJ, Chan DW, Getzenberg RH. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Research. 67: 5600-5. PMID 17575123 DOI: 10.1158/0008-5472.Can-07-0649 |
0.772 |
|
| 2007 |
Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW, Getzenberg RH. EPCA-2: a highly specific serum marker for prostate cancer. Urology. 69: 714-20. PMID 17445657 DOI: 10.1016/J.Urology.2007.01.097 |
0.856 |
|
| 2007 |
Cannon GW, Mullins C, Lucia MS, Hayward SW, Lin V, Liu BC, Slawin K, Rubin MA, Getzenberg RH. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. The Journal of Urology. 177: 610-4; discussion 61. PMID 17222644 DOI: 10.1016/J.Juro.2006.09.023 |
0.564 |
|
| 2007 |
Leman ES, Cannon GW, Track BJ, Sokoll LJ, Chan DW, Mangold LA, Partin AW, Nickel JC, Dimitrakov JD, Getzenberg RH. 1431: Further Analysis of Serum Based EPCA-2 as a Specific Prostate Cancer Associated Biomarker Journal of Urology. 177: 472-472. DOI: 10.1016/S0022-5347(18)31632-X |
0.849 |
|
| 2006 |
Nielsen ME, Gonzalgo ML, Schoenberg MP, Getzenberg RH. Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer. World Journal of Urology. 24: 499-508. PMID 17102951 DOI: 10.1007/S00345-006-0116-9 |
0.469 |
|
| 2006 |
Nielsen ME, Schaeffer EM, Veltri RW, Schoenberg MP, Getzenberg RH. Urinary markers in the detection of bladder cancer: what's new? Current Opinion in Urology. 16: 350-5. PMID 16905981 DOI: 10.1097/01.Mou.0000240308.62958.50 |
0.494 |
|
| 2006 |
Coffey DS, Getzenberg RH, DeWeese TL. Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect". Jama. 296: 445-8. PMID 16868303 DOI: 10.1001/Jama.296.4.445 |
0.436 |
|
| 2006 |
Balasubramani M, Day BW, Schoen RE, Getzenberg RH. Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Research. 66: 763-9. PMID 16424007 DOI: 10.1158/0008-5472.Can-05-3771 |
0.418 |
|
| 2006 |
Cannon GW, Getzenberg RH. 1354: A Serum-Based Assay for JM-27 Can Identify Men with Symptomatic Benign Prostatic Hyperplasia Journal of Urology. 175: 436-437. DOI: 10.1016/S0022-5347(18)33567-5 |
0.571 |
|
| 2006 |
Yeater DB, Mangold LA, Partin AW, Getzenberg RH. 851: Early Prostate Cancer Antigen and Prostate Specific Antigen: Two is better than One Journal of Urology. 175: 275-275. DOI: 10.1016/S0022-5347(18)33087-8 |
0.641 |
|
| 2006 |
Getzenberg RH. Molecular markers of urologic cancers Urologic Oncology: Seminars and Original Investigations. 24: 509. DOI: 10.1016/J.Urolonc.2006.07.001 |
0.534 |
|
| 2005 |
Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 66: 64-74. PMID 16399416 DOI: 10.1016/J.Urology.2005.08.065 |
0.406 |
|
| 2005 |
Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 66: 35-63. PMID 16399415 DOI: 10.1016/J.Urology.2005.08.064 |
0.479 |
|
| 2005 |
Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH. Highly specific urine-based marker of bladder cancer. Urology. 66: 1256-60. PMID 16360453 DOI: 10.1016/j.urology.2005.07.010 |
0.412 |
|
| 2005 |
Davies B, Chen J, Modugno F, Weissfeld J, Landsittel D, Dhir R, Nelson J, Getzenberg RH. Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer. The Journal of Urology. 174: 1767-70. PMID 16217280 DOI: 10.1097/01.Ju.0000177070.13987.Ce |
0.572 |
|
| 2005 |
Myers-Irvin JM, Van Le TS, Getzenberg RH. Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology. Cancer Research. 65: 7145-50. PMID 16103064 DOI: 10.1158/0008-5472.CAN-05-1142 |
0.318 |
|
| 2005 |
Roy-Burman P, Tindall DJ, Robins DM, Greenberg NM, Hendrix MJ, Mohla S, Getzenberg RH, Isaacs JT, Pienta KJ. Androgens and prostate cancer: are the descriptors valid? Cancer Biology & Therapy. 4: 4-5. PMID 16052746 DOI: 10.4161/Cbt.4.1.1563 |
0.607 |
|
| 2005 |
Minnery CH, Getzenberg RH. Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen. The Journal of Urology. 174: 375-9. PMID 15947693 DOI: 10.1097/01.ju.0000161598.24740.34 |
0.421 |
|
| 2005 |
Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel marker BLCA-1 for the detection of bladder cancer. The Journal of Urology. 174: 64-8. PMID 15947579 DOI: 10.1097/01.ju.0000162022.36772.a4 |
0.415 |
|
| 2005 |
Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer: a review. The American Journal of Gastroenterology. 100: 1393-403. PMID 15929776 DOI: 10.1111/J.1572-0241.2005.41427.X |
0.361 |
|
| 2005 |
Paul B, Dhir R, Landsittel D, Hitchens MR, Getzenberg RH. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Research. 65: 4097-100. PMID 15899799 DOI: 10.1158/0008-5472.Can-04-4523 |
0.682 |
|
| 2005 |
Slawin KM, Levitt JM, Roehrborn CG, McConnell JD, Getzenberg RH, Lucia MS, Peterson L, Noble WD, Lamb DJ, Mullins C, Star R, Kusek JW, Nyberg LM. 1286: The Relationship between PSA Isoforms and BPH-Related Prostate Volume at Baseline in the MTOPS Trial Journal of Urology. 173: 349-349. DOI: 10.1016/S0022-5347(18)35431-4 |
0.538 |
|
| 2005 |
Myers-Irvin J, Getzenberg RH. 850: Utilization of the Novel Marker, BLCA-1, for the Detection of Bladder Cancer Journal of Urology. 173: 231-231. DOI: 10.1016/S0022-5347(18)35019-5 |
0.479 |
|
| 2004 |
Getzenberg RH. Commentary on: Mobley AJ, Lam YW, Lau KM, Pais VM, Lesperance JO, Steadman B, et al. Monitoring the serological Proteome Colon, the latest modality in prostate cancer detection. J Urol 2004; 172: 331-7. Asian Journal of Andrology. 6: 283. PMID 15546017 |
0.434 |
|
| 2004 |
Guzey M, Luo J, Getzenberg RH. Vitamin D3 modulated gene expression patterns in human primary normal and cancer prostate cells. Journal of Cellular Biochemistry. 93: 271-85. PMID 15368355 DOI: 10.1002/Jcb.20182 |
0.537 |
|
| 2004 |
Guzey M, Jukic D, Arlotti J, Acquafondata M, Dhir R, Getzenberg RH. Increased apoptosis of periprostatic adipose tissue in VDR null mice. Journal of Cellular Biochemistry. 93: 133-41. PMID 15352170 DOI: 10.1002/Jcb.20172 |
0.576 |
|
| 2004 |
Shah US, Arlotti J, Dhir R, Lu S, Pirozzi G, Prakash K, Getzenberg RH. Androgen regulation of JM-27 is associated with the diseased prostate. Journal of Andrology. 25: 618-24. PMID 15223850 |
0.558 |
|
| 2004 |
Kakehi Y, Segawa T, Wu XX, Kulkarni P, Dhir R, Getzenberg RH. Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia. The Prostate. 59: 351-6. PMID 15065082 DOI: 10.1002/pros.10365 |
0.437 |
|
| 2004 |
Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R, Getzenberg RH. Early identification of individuals with prostate cancer in negative biopsies. The Journal of Urology. 171: 1419-23. PMID 15017188 DOI: 10.1097/01.ju.0000116545.94813.27 |
0.614 |
|
| 2004 |
Sakamoto S, Yokoyama M, Zhang X, Prakash K, Nagao K, Hatanaka T, Getzenberg RH, Kakehi Y. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Endocrinology. 145: 2929-40. PMID 14988385 DOI: 10.1210/en.2003-1350 |
0.48 |
|
| 2004 |
Van Le TS, Myers J, Konety BR, Barder T, Getzenberg RH. Functional characterization of the bladder cancer marker, BLCA-4. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 1384-91. PMID 14977841 |
0.375 |
|
| 2004 |
Brünagel G, Schoen RE, Getzenberg RH. Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps. Journal of Cellular Biochemistry. 91: 365-74. PMID 14743395 DOI: 10.1002/jcb.10695 |
0.4 |
|
| 2004 |
Shah US, Getzenberg RH. Fingerprinting the diseased prostate: associations between BPH and prostate cancer. Journal of Cellular Biochemistry. 91: 161-9. PMID 14689588 DOI: 10.1002/Jcb.10739 |
0.62 |
|
| 2004 |
Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R, Getzenberg RH. 640: Identification of Individuals with Prostate Cancer by Examination of “Negative Biopsies” Journal of Urology. 171: 170-170. DOI: 10.1016/S0022-5347(18)37902-3 |
0.669 |
|
| 2004 |
Van Le T, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH. 260: BLCA-4, A Highly Specific Marker Urine-Based Markerof Bladder Cancer Journal of Urology. 171: 68-68. DOI: 10.1016/S0022-5347(18)37522-0 |
0.508 |
|
| 2003 |
Sakamoto S, Yokoyama M, Prakash K, Tsuruha J, Masamoto S, Getzenberg RH, Kakehi Y. Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia. Journal of Biomolecular Screening. 8: 701-11. PMID 14711396 DOI: 10.1177/1087057103259159 |
0.444 |
|
| 2003 |
Kasai M, Guerrero-Santoro J, Friedman R, Leman ES, Getzenberg RH, DeFranco DB. The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines. Cancer Research. 63: 4927-35. PMID 12941817 |
0.749 |
|
| 2003 |
Leman ES, Arlotti JA, Dhir R, Getzenberg RH. Vitamin D and androgen regulation of prostatic growth. Journal of Cellular Biochemistry. 90: 138-47. PMID 12938163 DOI: 10.1002/Jcb.10605 |
0.796 |
|
| 2003 |
Leman ES, DeMiguel F, Gao AC, Getzenberg RH. Regulation of androgen and vitamin d receptors by 1,25-dihydroxyvitamin D3 in human prostate epithelial and stromal cells. The Journal of Urology. 170: 235-40. PMID 12796696 DOI: 10.1097/01.Ju.0000060117.61770.35 |
0.776 |
|
| 2003 |
Brünagel G, Shah U, Schoen RE, Getzenberg RH. Identification of calreticulin as a nuclear matrix protein associated with human colon cancer. Journal of Cellular Biochemistry. 89: 238-43. PMID 12704787 DOI: 10.1002/jcb.10502 |
0.422 |
|
| 2003 |
Leman ES, Getzenberg RH. Effects of 1,25-dihydroxyvitamin D3 on the distribution of androgen and vitamin D receptors in human prostate neonatal epithelial cells. Journal of Cellular Biochemistry. 88: 609-22. PMID 12532336 DOI: 10.1002/Jcb.10371 |
0.791 |
|
| 2003 |
Leman ES, Madigan MC, Brünagel G, Takaha N, Coffey DS, Getzenberg RH. Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer. Journal of Cellular Biochemistry. 88: 599-608. PMID 12532335 DOI: 10.1002/Jcb.10368 |
0.843 |
|
| 2003 |
Getzenberg RH. Urine-Based Assays for Bladder Cancer Laboratory Medicine. 34: 613-617. DOI: 10.1309/MRF2YWMVUAVFB8EC |
0.388 |
|
| 2002 |
Brünagel G, Schoen RE, Bauer AJ, Vietmeier BN, Getzenberg RH. Nuclear matrix protein alterations associated with colon cancer metastasis to the liver. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 3039-45. PMID 12374670 |
0.311 |
|
| 2002 |
Leman ES, Getzenberg RH. Nuclear matrix proteins as biomarkers in prostate cancer. Journal of Cellular Biochemistry. 86: 213-23. PMID 12111991 DOI: 10.1002/Jcb.10218 |
0.838 |
|
| 2002 |
Leman ES, Arlotti JA, Dhir R, Greenberg N, Getzenberg RH. Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer. Journal of Cellular Biochemistry. 86: 203-12. PMID 12111990 DOI: 10.1002/Jcb.10216 |
0.844 |
|
| 2002 |
Konety BR, Getzenberg RH. Vitamin D and prostate cancer. The Urologic Clinics of North America. 29: 95-106, ix. PMID 12109360 |
0.564 |
|
| 2002 |
Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, Kakehi Y, Getzenberg RH. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proceedings of the National Academy of Sciences of the United States of America. 99: 7598-603. PMID 12032329 DOI: 10.1073/pnas.112191399 |
0.435 |
|
| 2002 |
Konety BR, Somogyi G, Atan A, Muindi J, Chancellor MB, Getzenberg RH. Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitamin D(3) (calcitriol) using a microdialysis technique. Urology. 59: 947-52. PMID 12031392 |
0.546 |
|
| 2002 |
Brünagel G, Vietmeier BN, Bauer AJ, Schoen RE, Getzenberg RH. Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Research. 62: 2437-42. PMID 11956108 |
0.345 |
|
| 2002 |
Nguyen T, Konety B, Myers J, Getzenberg R. A novel highly specific and sensitive urine-based assay for the detection of bladder cancer European Urology Supplements. 1: 49. DOI: 10.1016/S1569-9056(02)80181-6 |
0.441 |
|
| 2001 |
Krill D, DeFlavia P, Dhir R, Luo J, Becich MJ, Lehman E, Getzenberg RH. Expression patterns of vitamin D receptor in human prostate. Journal of Cellular Biochemistry. 82: 566-72. PMID 11500934 DOI: 10.1002/JCB.1185 |
0.461 |
|
| 2001 |
Konety BR, Getzenberg RH. Urine based markers of urological malignancy. The Journal of Urology. 165: 600-11. PMID 11176445 DOI: 10.1097/00005392-200102000-00081 |
0.375 |
|
| 2001 |
Arlotti JA, Cimino TS, Nguyen TS, Dhir R, Thomas A, Jaynes JM, Caldwell AL, Getzenberg RH. Efficacy of a synthetic lytic peptide in the treatment of prostate cancer Urologic Oncology. 6: 97-102. DOI: 10.1016/S1078-1439(00)00120-4 |
0.454 |
|
| 2000 |
Konety BR, Nguyen TT, Brenes G, Lewis N, Saul M, Nelson JB, Getzenberg RH. Evaluation of the effect of spinal cord injury on serum PSA levels. Urology. 56: 82-6. PMID 10869630 DOI: 10.1016/S0090-4295(00)00548-3 |
0.434 |
|
| 2000 |
Konety BR, Getzenberg RH. Nuclear structural proteins as biomarkers of cancer. Journal of Cellular Biochemistry. 183-91. PMID 10629118 DOI: 10.1002/(Sici)1097-4644(1999)75:32+<183::Aid-Jcb22>3.0.Co;2-A |
0.419 |
|
| 2000 |
KONETY BR, NGUYEN TT, BRENES G, SHOLDER A, LEWIS N, BASTACKY S, POTTER DM, GETZENBERG RH. CLINICAL USEFULNESS OF THE NOVEL MARKER BLCA-4 FOR THE DETECTION OF BLADDER CANCER Journal of Urology. 164: 634-639. DOI: 10.1016/S0022-5347(05)67269-2 |
0.332 |
|
| 2000 |
KONETY BR, LEMAN E, VIETMEIER B, ARLOTTI J, DHIR R, GETZENBERG RH. IN VITRO AND IN VIVO EFFECTS OF VITAMIN D (CALCITRIOL) ADMINISTRATION ON THE NORMAL NEONATAL AND PREPUBERTAL PROSTATE Journal of Urology. 164: 1812-1818. DOI: 10.1016/S0022-5347(05)67112-1 |
0.819 |
|
| 2000 |
Stein G, Berezney R, Getzenberg R. Nuclear structure and cancer Journal of Cellular Biochemistry. 79: 1-2. DOI: 10.1002/1097-4644(2000)79:35+<1::Aid-Jcb1120>3.0.Co;2-E |
0.458 |
|
| 1999 |
Konety BR, Nangia AK, Nguyen TS, Thomas A, Getzenberg RH. Effect of prenatal vitamin D (calcitriol) exposure on the growth and development of the prostate. The Prostate. 41: 181-9. PMID 10517876 DOI: 10.1002/(Sici)1097-0045(19991101)41:3<181::Aid-Pros5>3.0.Co;2-7 |
0.56 |
|
| 1999 |
Krill D, Stoner J, Konety BR, Becich MJ, Getzenberg RH. Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture. Urology. 54: 171-7. PMID 10414747 DOI: 10.1016/S0090-4295(99)00103-X |
0.414 |
|
| 1999 |
Nguyen TT, Vietmeier BN, Bastacky S, Konety BR, Getzenberg RH. Utilization Of The Bladder Cancer Specific Nuclear Matrix Protein: Blca-4, For The Detection Of Bladder Cancer The Journal of Urology. 149. DOI: 10.1097/00005392-199904010-00597 |
0.524 |
|
| 1998 |
Nangia AK, Butcher JL, Konety BR, Vietmeier BN, Getzenberg RH. Association of vitamin D receptors with the nuclear matrix of human and rat genitourinary tissues. The Journal of Steroid Biochemistry and Molecular Biology. 66: 241-6. PMID 9744521 DOI: 10.1016/S0960-0760(98)00039-9 |
0.321 |
|
| 1998 |
Green JE, Greenberg NM, Ashendel CL, Barrett JC, Boone C, Getzenberg RH, Henkin J, Matusik R, Janus TJ, Scher HI. Workgroup 3: transgenic and reconstitution models of prostate cancer. The Prostate. 36: 59-63. PMID 9650918 DOI: 10.1002/(Sici)1097-0045(19980615)36:1<59::Aid-Pros11>3.0.Co;2-H |
0.592 |
|
| 1997 |
Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 50: 999-1006. PMID 9426741 DOI: 10.1016/S0090-4295(97)00408-1 |
0.514 |
|
| 1997 |
Replogle-Schwab R, Pienta KJ, Getzenberg RH. The utilization of nuclear matrix proteins for cancer diagnosis. Critical Reviews in Eukaryotic Gene Expression. 6: 103-13. PMID 8855384 DOI: 10.1615/CritRevEukarGeneExpr.v6.i2-3.10 |
0.409 |
|
| 1995 |
Osborn JL, Getzenberg RH, Trump DL. Spinal cord compression in prostate cancer Journal of Neuro-Oncology. 23: 135-147. PMID 7543940 DOI: 10.1007/Bf01053418 |
0.396 |
|
| 1993 |
Pienta KJ, Murphy BC, Getzenberg RH, Coffey DS. The Tissue Matrix and The Regulation of Gene Expression in Cancer Cells Advances in Molecular and Cell Biology. 7: 131-156. DOI: 10.1016/S1569-2558(08)60238-6 |
0.304 |
|
| 1990 |
Getzenberg RH, Coffey DS. Tissue specificity of the hormonal response in sex accessory tissues is associated with nuclear matrix protein patterns Molecular Endocrinology. 4: 1336-1342. PMID 2233749 DOI: 10.1210/Mend-4-9-1336 |
0.442 |
|
| 1990 |
Getzenberg RH, Pienta KJ, Coffey DS. The tissue matrix: Cell dynamics and hormone action Endocrine Reviews. 11: 399-417. PMID 2226348 DOI: 10.1210/Edrv-11-3-399 |
0.301 |
|
| Show low-probability matches. |